TB-500 / TB4: Mechanistic Overview
internal_protocol · preclinical · status: needs_provider_review
Metadata
Author: Axiom Knowledge Base
Citation: Internal reference summary compiled for the Axiom knowledge base (2026).
Embedding: pending
File: signed link
Summary (generated — provider review required)
TB-500 is a synthetic fragment of Thymosin beta-4 (TB4), an actin-binding regulatory peptide. The evidence base is largely preclinical. Mechanism: TB4 promotes actin sequestration, cell migration, angiogenesis, and modulation of inflammation, and has been studied in animal models of tissue, cardiac, and corneal repair.
The original source document remains the source of truth. Generated summaries are not authoritative.
Linked assets (4) · phenotypes (0)
evidence_reference, mechanism, safety_reference, dosing_reference
Evidence claims (4) · review items (3)
regulatory · pending
TB-500 is a synthetic fragment of Thymosin beta-4 (TB4), an actin-binding regulatory peptide.
mechanism · pending
Mechanism: TB4 promotes actin sequestration, cell migration, angiogenesis, and modulation of inflammation, and has been studied in animal models of tissue, cardiac, and corneal repair.
safety · pending
Safety: human data are limited and regulatory status varies; sourcing/purity are practical concerns.
dosing · pending
Mechanistic background for provider review only — not a treatment recommendation or dosing guidance.
Extracted chunks (1)
79 approx tokens across 1 chunks.